Skip to main content
. Author manuscript; available in PMC: 2018 Oct 2.
Published in final edited form as: Gynecol Oncol. 2018 May 24;150(2):361–369. doi: 10.1016/j.ygyno.2018.05.024

Table 3:

Completed clinical trials in TIL ACT trials in ovarian cancer

Author Phase Pre-conditioning chemotherapy Ovarian Cancer Eligibility TIL IL-2 dose and regimen Study Size (patients) ORR (%) CR (%)
Aoki et al. 1991 III Cisplatin or FCAP Stage III-IV IV None 17 82 0
Freedman et al. 1994 I None Bolus Intraperitonal Low-dose IL-2 intraperitoneal 11 0 0
Ikarashi et al. 1994 I/II FCAP or CAP Stage II, III or IV IV None 12 – –
Fujita et al. 1995 I/II FCAP or CAP Stage II, III or IV IV None 13 – –
Freedman et al. 2000 I None Bolus Intraperitoneal IL-2 or IFN-γ 2 0 0

Abbreviations: TIL, tumor infiltrating lymphocytes; FCAP, 5-fluorouracil, cyclophosphamide, adriamycin, cisplatin; CAP, cyclophosphamide, Adriamycin, cisplatin; IL-2, interleukin-2; IFN-γ, interferon-gamma; ORR, overall response rate; CR, complete response; pt(s), patient(s).